Loading
A phase 3 trial of Brentuximab vedotin, Rituximab, Lenalidomide in diffuse large b-cell lymphoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT04404283 by Seagen, a wholly owned subsidiary of Pfizer, with 239 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2026-01-23. Interventions recorded: Brentuximab vedotin, Rituximab, Lenalidomide, Placebo. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Monoclonal antibodies.
Shares CD20, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab.
Shares POLARGO, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares STARGLO, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Monoclonal antibodies.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Monoclonal antibodies.